AAN

As more research is collected about Tecfidera's usage since clinical trials and approval there continue to be signs that it can be a good treatment option for patients with multiple sclerosis, especially in the earliest stages.

Technology has many uses in modern life. Recent research looked at whether advanced games and other apps could help improve cognitive function in patients with multiple sclerosis.

Treating patients suffering from primary generalized tonic-clonic (PGTC) seizures with once-daily 8mg doses of adjunctive perampanel (Fycompa/Eisai) can effectively control the seizures, recent study finds.

The Zika virus, the latest virus to warrant public health concerns, could be associated with an autoimmune disorder similar to multiple sclerosis.

Eslicarbazepine acetate, a once-a-day epilepsy drug, can prevent onset of seizures as well as the twice-daily drug carbamazepine, new research reports.

Physicians can now more accurately recognize concussions in athletes by using an advanced form of ultrasound.

Clemastine fumarate, an over-the-counter drug used to fight allergies, can also treat vision damage in patients with multiple sclerosis (MS).

When the American Academy of Neurology met in Washington DC results were presented from studies covering a variety of topics and at different levels of completion. Many of those results could eventually have long lasting impacts on the field.

Patients, especially young patients with some of the rarer forms of epilepsy may benefit from taking cannabidiol for their conditions. While based from marijuana plants the medication does not have many of the traits of other forms of medical marijuana.

A recent study conducted of patients with multiple sclerosis showed that a change could be coming in the field. Just as patients said they wanted to be more involved in their choice of treatment options, their healthcare professionals said they encouraged feedback from the patients.

As part of the overall picture of multiple sclerosis treatment optic neuritis is one of the early stages of the condition. The studies looked at sodium channels that show promise for future multiple sclerosis patients even if it is not in the field.

After diagnosing a patient complaining of dizziness it falls to the doctors seeing them to find the proper course of treatment. There are also efforts underway to develop new methods of treatment including modern devices that could be used in the future.

Many patients who come to the emergency department are seen and receive any number of diagnoses based on their symptoms and the length of time of their issues. How those symptoms are addressed can make a significant difference in their overall care.

Patients diagnosed with Parkinson's disease face a wide range of physical ailments with their condition. One of the lesser addressed areas is the psychological aspects they face as well. Therapeutic alternatives are being developed to help treat psychosis in this particular patient group.

Medications in general can take a long time to develop. Depending on the condition they treat that process can be even longer as more questions have to be answered before they can be introduced to the field. This is particularly true of multiple sclerosis treatments.

As a treatment for multiple sclerosis teriflunomide has shown benefits over a long development period and has proven effective in the treatment of patients with the relapsing-remitting form of the condition.

For as many drugs and therapies as there are for multiple sclerosis some are more aggressive than others. Alemtuzumab's approach is more on the aggressive end of the spectrum.

Epilepsy is a well known condition both in the medical community and in the general public. Despite that there is still a considerable amount of misinformation that can affect a person's willingness to seek treatment and know what to expect during the process.

Using the new guidelines set forth by the American Academy of Neurology should help doctors and patients understand how best to proceed as more is learned about the affects of first seizures and factors that could contribute to future occurrences.

When a patient suffers their first seizure their initial reaction may be to seek immediate medical and pharmaceutical care to ensure there are no subsequent events. Doctors themselves may look for quick fixes rather than longer lasting remedies.

Patients who suffer their first seizure are expected to have several questions. In some instances, one question may be why their doctor is waiting until a second seizure to begin treatment. A new guideline from the American Academy of Neurology looked to answer that question for doctors and patients alike.

As more is learned about the diagnosis and treatment of CIDP the medical community is also learning how best to work with patients with the condition.

Sometimes symptoms of CIDP can closely resemble those of other conditions. In light of this it is important for doctors to take a closer look to ensure a proper diagnosis is made.

Doctors treating patients with pediatric multiple sclerosis often turn to the same treatments as adult patients. While there are some unique characteristics and more work is being done in the field, these seem to give the best hope of maintaining a high quality of life for the young patients.

Getting a proper diagnosis for pediatric multiple sclerosis is not an easy task and requires a partnership between doctors, patients and their families.

A lot of attention in the field of multiple sclerosis is being dedicated to neuroprotection and remyelination. Whether these can someday lead to more effective treatments remains to be seen but there is optimism among doctors and researchers alike.

A lot of work is being put into developing ways to diagnose and treat patients with Alzheimer's Disease now. Even as work for the present is being done researchers are are also looking toward the future and what could be coming down the road.

The understanding of Alzheimer's Disease has shown a lot of progression in recent years. One area that has not found a definitive new direction is diagnosis, which typically can only be done through autopsy. New technology could allow doctors to see the disease before it affects a person's life.

As with all forms of medicine there are challenges associated with treating patients with hyperkinetic movement disorders. How doctors tackle those challenges can range from work in specialty clinics to consulting with patients through telemedicine.

The opioid epidemic began nearly 30 years ago and since that time small steps have been taken to reverse its effects. The question remains whether too much damage has already been done to fix the problems in a timely manner.